Clinical trial NCT00165633: A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma
Official title: A Randomized, Placebo-Controlled, Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
PHASE3
Conditions: Hepatocellular Carcinoma
Keywords: Hepatocellular
Carcinoma
Hepatitis C Virus
Hepatitis B Virus
recurrence
Vitamin K2
E0167
Lead sponsor: Eisai Inc.
Sponsor class: INDUSTRY
First posted: 2005-09-14
Enrollment: 540
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the superiority of inhibitory effects and safety of Menatetrenone (E0167) on recurrence in patients with hepatocellular carcinoma.

Detailed description: The study was conducted as a multicenter, randomized, parallel, placebo-controlled, double-blind comparative clinical study. Patients were randomly assigned in a double-blind manner to receive 45 or 90 mg/day of oral vitamin K2 or an identical-appearing placebo. Study drug was administered orally three times daily after meals until recurrence.

Eligibility criteria: Inclusion Criteria:

1. 20 years or older at the time of obtaining consent.
2. Systemic conditions are 0 to 2 score of Performance Status (according to Eastern Cooperative Oncology Group: ECOG).
3. Diagnosis of hepatocellular carcinoma is based on the following 1) or 2).

   * 1) Patients who are confirmed to have early tumor stain and typical finding(s) of hepatocellular carcinoma with CT or MRI imaging
   * 2) Patients who underwent tumor biopsy and are histopathologically diagnosed as hepatocellular carcinoma
4. Primary onset or recurrence of hepatocellular carcinoma is not more than 1 time.
5. Patients who underwent the following 1) or 2) within 90 days prior to registration to determine therapeutic effect.

   * 1) Patients who underwent local therapy to achieve complete hepatonecrosis and are confirmed to have complete hepatonecrosis with CT imaging or MRI.
   * 2) Patients who underwent surgical treatment(s) and are confirmed not to have residual tumor with CT or MRI imaging.
6. Patients who meet the following items to determine liver function:

   * 1) Albumin is 2.8 g/dL or above
   * 2) Total bilirubin is under 2.0 mg/dL
   * 3) Prothrombin activation is 40% or above
7. Patients who are given full explanation of study participation (including cancer notification) and submit written consent forms with their understanding as well as voluntary will for this study.

Exclusion Criteria:

1. Hepatocellular carcinoma:

   * 1) Patients who have extrahepatic metastasis
   * 2) Patients who have portal invasion
   * 3) Patients who experienced with systemic administration of anti-malignant tumor drugs to treat hepatocellular carcinoma
   * 4) Patients treated with transcatheter arterial chemoembolization (TAE) alone as a non-local therapy for hepatocellular carcinoma
2. Hepatitis:

   -- 1) Patients of (a) or (b) previously treated with interferon preparations (including clinical studies).
   * (a) Patients with chronic hepatitis C virus (HCV) showing HCV-RNA negative
   * (b) Patients with viral hepatitis treated with interferon preparations within the last 2 years (from the same day, 6 months earlier to the day of obtaining consent forms)
   * (c) Patients with encephalopathy in which pharmacotherapy is ineffective
   * (d) Patients with ascites or pleural effusion that cannot be managed with diuretics
3. Systemic conditions:

   * 1) Patients unable to receive oral administration
   * 2) Patients with a history of gastrectomy or extensive resection of digestive tract
   * 3) Patients who are suspected to have biliary occlusion, choleretic disorder, cholecystectomy, or malabsorption of liposoluble agents
   * 4) Patients with complicated serious diseases such as cardiovascular (e.g., myocardial infarction), hematological (e.g., aplastic anemia), and/or renal dysfunctions (e.g., acute and chronic renal failure)
   * 5) Patients with multiple cancers (within a 5-year cancer-free period \[from the same day of 5 years earlier to the day of obtaining consent forms\])
4. Drug administration:

   * 1) Patients on warfarin potassium therapy
   * 2) Patients with a known history of drug allergy to E0167 or its ingredients
   * 3) Patients who received vitamin K preparations within the recent 6 months (from the same day of 6 month earlier to the day of obtaining consent forms)
5. Other exclusion criteria

   * 1) Women of pregnant, lactating, childbearing potential, or with the intention of becoming pregnant
   * 2) Patients who are presently participating in another clinical study (except for follow-up surveys for study outcomes)
   * 3) Patients who are judged to be ineligible for study entry by the investigator or subinvestigator

Primary outcomes:
measure: Relapse-free survival period.
timeFrame: Every 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Fukuoka
country: Japan
state: Fukuoka-prefecture
city: Kurume
country: Japan
state: Fukuoka-prefecture
city: Naka
country: Japan
state: Hiroshima-prefecture
city: Sapporo
country: Japan
state: Hokkaido-prefecture
city: Sapporo
country: Japan
state: Hokkaido-prefecture
city: Hitachi
country: Japan
state: Ibaraki-prefecture
city: Morioka
country: Japan
state: Iwate-prefecture
city: Kawasaki
country: Japan
state: Kanagawa-prefecture
city: Kanazawa
country: Japan
state: Kanazawa-prefecture
city: Senndai
country: Japan
state: Miyagi-prefecture
city: Niigata
country: Japan
state: Niigata-prefecture
city: Oita
country: Japan
state: Oita-prefecture
city: Kurashiki
country: Japan
state: Okayama-prefecture
city: Okayama
country: Japan
state: Okayama-prefecture
city: Okayama
country: Japan
state: Okayama-prefecture
city: Moriguchi
country: Japan
state: Osaka-prefecture
city: Osakasayama
country: Japan
state: Osaka-prefecture
city: Osaka
country: Japan
state: Osaka-prefecture
city: Osaka
country: Japan
state: Osaka-prefecture
city: Osaka
country: Japan
state: Osaka-prefecture
city: Saga
country: Japan
state: Saga-prefecture
city: Saga
country: Japan
state: Saga-prefecture
city: Shizuoka
country: Japan
state: Shizuoka-prefecture
city: Bunkyo-ku
country: Japan
state: Tokyo
city: Chiyoda-ku
country: Japan
state: Tokyo
city: Setagaya-ku
country: Japan
state: Tokyo
city: Shibuya-ku
country: Japan
state: Tokyo
city: Shinjuku-ku
country: Japan
state: Tokyo
city: Wakayama
country: Japan
state: Wakayama-prefecture
city: Ube
country: Japan
state: Yamaguchi-prefecture
Study officials:
affiliation: Eisai Co., Ltd - Development Clinical Research Department. Clinical Research Center
name: Nozomu Koyanagi
role: STUDY_DIRECTOR
References: